Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actelion Ltd
Pivotal Pulmonary Arterial Hypertension Study Published in the Lancet Concludes That Bosentan Tracleer Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
July 11th, 2008
Actelion Ltd announced that data published in The Lancet(1) show that, in mildly symptomatic pulmonary arterial hypertension (PAH) patients (WHO functional class II - WHO FC II), bosentan (Tracleer(R)) prevented clinical deterioration by significantly delaying time to clinical worsening and reduced the number of patients worsening to WHO FC III/IV. A significant reduction in pulmonary vascular resistance and a positive trend in increasing the 6MWD were also observed. The randomized, placebo-controlled EARLY (Endothelin Antagonist tRial in miLdlY symptomatic PAH patients) trial is the first and only trial conducted exclusively in a dedicated FC II PAH patient population. ...
Source: Health Business Week (2008-07-11)
|
|
Advertisement |
|
|
|
